One disadvantage of direct anticoagulant drug is the lack of an antidote, which may become relevant in patients with traumatic brain injury. A 77-years old man with atrial fibrillation and syncope received dabigatran despite recurrent falls. Due to a ground-level-fall, he suffered from subarachnoidal and intraparenchymal hemorrhages, subdural hematoma and brain edema with a midline shift. Despite osteoclastic trepanation and hematoma-evacuation he remained comatose and died seven days later without regaining consciousness. Most probably, decreased dabigatran clearance due to increased age might have contributed to the fatal course. We suggest withholding anticoagulant therapy in patients with unexplained falls. If anticoagulant therapy is deemed necessary, vitamin-K-antagonists with their potential for laboratory monitoring and reversal of anticoagulant activity should be preferred.
Introduction
Dabigatran, a direct thrombin inhibitor, is one of the direct anticoagulant drugs (DOACs) which are increasingly used in patients with atrial fibrillation (AF) for prevention of embolism. Dabigatran has been compared with the vitamin-K-antagonist (VKA) warfarin in the randomized evaluation of long-term anticoagulant therapy trial (RE-LY). [1] In that trial, the rates of ischemic strokes and intracranial haemorrhages were lower with dabigatran than with warfarin. [2] Patients with recurrent falls were excluded from RE-LY. [1] In real life, however, patients who are prone to falls are prescribed DOACs because physicians believe them to be "safer" than VKA. One of the disadvantages of the DOACs (Table 1) , the lack of an antidote for prompt reversal of the anticoagulant effect, may become relevant in traumatic brain injury as illustrated by the following case. In June 2014, he fell from his chair without any prodromi and hit his head. He had taken his last dabigatran tablet 2 h before the accident. His wife called for the emergency service who found him soporous with a Glasgow coma scale (GCS) of 12. On admission, he started to vomit requiring intubation. Cerebral computed tomography (CCT) showed extensive subarachnoidal and intraparenchymal hemorrhages, subdural hematoma and brain edema with a midline shift ( Figure 1 ). The results of the blood tests are listed in Table 2 . The prolonged thrombin time indicated anticoagulant activity of dabigatran. Interrogation of the pacemaker showed AF and no dysfunction at the time of the fall. Due to the massive bleeding, the midline shift and the neurologic deterioration it was decided to perform surgery 4 h after the fall, 6 h after he had taken the last dabigatran dose. Osteoklastic trepanation and evacuation of the subdural hematoma were carried out, and a left-sided parenchymal probe was inserted. For correction of his anticoagulation therapy he received 3000 IU human prothrombin complex concentrate and 15 µg desmopressin pre-and intraoperatively. The postoperative CCT showed an increase in the size of the haemorrhage (Figure 2 ). The patient remained comatose with a GCS of 3 and died 7 days later without regaining consciousness.
Discussion
Head trauma in the presented patient was severe and it is questionable if the outcome would have been different if he had not been anticoagulated. There are indications that the pathophysiology of traumatic intracranial hemorrhages differs from spontaneous intracranial hemorrhage due to extensive endothelial activation exacerbating prothrombotic and proinflammatory signaling pathways in traumatic intracranial hemorrhage. [3] The influence of dabigatran on traumatic brain injury has only been investigated in animal models, so far. [4] Little is known about patients who suffered from traumatic brain injury in the DOAC-investigating trials. There are indications from RE-LY that traumatic intracerebral haemorrhages under dabigatran may have a higher mortality then under warfarin. [2] In this trial, 22 traumatic intracranial haemorrhages occurred under dabigatran (intracerebral n = 4, subdural n = 15, subarachnoid n = 3), and 6 of them (27%) were fatal. In the patients randomized to warfarin, 46 traumatic intracranial haemorrhages occurred (intracerebral n = 4, subdural n = 16, subarachnoid n = 4), and only 5 of them (11%) were fatal. No details were reported how these patients were treated and if they underwent surgery. [2] In addition to RE-LY, there are case reports which indi- [5] 85/F MHT SDH, MS HD attempt failed Burr hole drainage Neurologically intact [6] 94/M GLF SDH, MS FEIBA, HD Burr hole drainage Mild hemiparesis [7] 80/M GLF SDH Vitamin K ND Neurologically intact [8] NR GLF IP NR Craniotomy Dead [9] 83/M GLF IP, tSAH, SDH rFVII ND Dead [10] 88/F GLF tSAH, SDH PCC, rFVII, HD ND Recovered [11] 87/F NS CSDH ND Burr hole evacuation Fully recovered [11] 80/F GLF CSDH PCC Burr hole evacuation Fully recovered [11] 86/M GLF CSDH ND Burr hole evacuation Fully recovered [11] 74/M GLF CSDH ND Burr hole evacuation Fully recovered [11] 87/F* GLF tSAH ND ND NI [11] 87/F* GLF IP ND ND NI [12] 79/F GLF IP, MS ND ND Dead [12] 72/M GLF tSAH FFP ND Neurologically intact [15] NR cate that the therapy of fall-associated brain injuries in patients under dabigatran is difficult since there is no specific antidote available, as listed in Table 3 . [5] [6] [7] [8] [9] [10] [11] [12] From these cases it can be inferred that patients with chronic subdural hematoma under dabigatran have a better prognosis than patients with acute subdural hematoma which is similar to patients under VKA-or antiplatelet-therapy. [13] Parra, et al. [14] reported five patients with closed head injury secondary to ground-level falls under dabigatran. All patients had repeated CCTs after reversal of anticoagulation, and in four patients, new or expanded haemorrhages were seen. Two of these five patients died. During the same time, 15 patients under warfarin (n =12 with AF) and 25 without anticoagulation (n = 0 with AF) were treated after closed head injury and none of these patients died. [3] Alonso, et al. [15] reported about intracranial haemorrhages in AF patients treated with dabigatran or warfarin by analysing healthcare utilization claims in the Truven Health Marketscan Research Database. They reported that 45 of the 101 dabigatran-treated patients suffered from traumatic haemorrhages but traumatic and nontraumatic intracerebral haemorrhages were not compared regarding haemorrhage subtype, therapy or mortality. Among 11 patients with life-threatening dabigatran-related bleeding events, reported by Ross, et al., [16] four patients had traumatic intracerebral haemorrhages and one of them died. Neurosurgeons are frequently involved in the management of anticoagulation-related intracerebral hemorrhages. Strategies to reverse VKA comprise fresh frozen plasma, prothrombin complex concentrates, vitamin K, and recombinant activated factor VII. However, reversal of anticoagulation may not always result in good clinical outcome which is probably related to the severity of the initial hemorrhage. [17] As compared with VKA, pharmacologic strategies to reverse dabigatran or other DOACs are lacking and experience is limited mostly to case reports as listed in Table 3 . Multiple measures are taken, like in our patient, to reverse the anticoagulant effect of dabigatran. This polypragmatic approach is of limited therapeutic success. Since dabigatran has a low protein binding, elimination by haemodialysis or hemofiltration is a possible therapy, however in trauma-patients this measure is difficult to perform and only applied rarely. [6, 10, 16] In our patient, haemodialysis was not carried out because of the rapid progression of the neurologic deterioration necessitating urgent surgery. At present, there is no specific antidote available for dabigatran. Idarucizumab, an investigational fully humanized antibody fragment, is under investigation. Data from a, so far unpublished, phase I study showed that idarucizumab was able to achieve immediate, complete and sustained reversal of dabigatran-induced anticoagulation in healthy humans. According to the manufacturer, a global phase III study, RE-VERSE AD™, is under way in patients taking dabigatran who have uncontrolled bleeding or require emergency surgery or procedures.
Frail elderly people, like our patient, were not represented in DOAC-investigating trials due to various exclusion criteria, and only a third of patients in these trials were > 75 years. From RE-LY, a subgroup analysis showed that in patients ≥ 75 years extracranial bleeding risk was higher (4.1%/4.7% per year) under 220/300 mg/d dabigatran vs. 3.4%/year under warfarin. [18] One factor for the increased bleeding risk in elderly patients might be the decreased clearance of dabigatran: dabigatran concentration is increased 1.3-fold in patients aged 65-75 years and 1.7-fold in those ≥ 75 years; these increases correspond to a decreased clearance of 0.66% for each year of age greater than the median age of 68 years. [19] The risk of falls is the most frequent reason for not prescribing VKAs to elderly patients. [20] In patients aged ≥ 81 years, the risk of non-accidental falls was 2.5 times higher in patients with AF compared to those without. [21] A history of falls is the strongest risk factor for subsequent bleeding events, strokes and all-cause mortality in elderly AF-patients under anticoagulation. [22, 23] The use of DOACs will neither solve the problem of falls nor of fall-associated traumatic bleeding, as illustrated by the presented case.
In conclusion, we suggest withholding anticoagulant therapy in patients with unexplained falls as long as no therapy for their falls has been established. If anticoagulant therapy is deemed necessary, VKA should be preferred over DOACs, as long as no antidotes for DOACs and reliable tests for laboratory monitoring are available.
